Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.

× No keyword cloud information.

14 in total

1. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.

Authors: I R Reid; G C Nicholson; R S Weinstein; D J Hosking; T Cundy; M A Kotowicz; W A Murphy; S Yeap; S Dufresne; A Lombardi; T A Musliner; D E Thompson; A J Yates
Journal: Am J Med Date: 1996-10 Impact factor: 4.965

2. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Authors: E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering
Journal: J Clin Endocrinol Metab Date: 1996-03 Impact factor: 5.958

3. Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy.

Authors: E S Siris; R E Canfield; T P Jacobs; K E Stoddart; P J Spector
Journal: Metab Bone Dis Relat Res Date: 1981

4. Treatment of Paget's disease of bone with alendronate.

Authors: A Lombardi
Journal: Bone Date: 1999-05 Impact factor: 4.398

Review 5. Goals of treatment for Paget's disease of bone.

Authors: E S Siris
Journal: J Bone Miner Res Date: 1999-10 Impact factor: 6.741

6. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors: D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal: Lancet Date: 1996-12-07 Impact factor: 79.321

7. Alendronate in the treatment of Paget's disease of bone.

Authors: S A Khan; S Vasikaran; E V McCloskey; M N Benéton; S Rogers; L Coulton; J Orgee; G Coombes; J A Kanis
Journal: Bone Date: 1997-03 Impact factor: 4.398

8. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.

Authors: P D Delmas; M C Chapuy; E Vignon; S Charhon; D Briancon; C Alexandre; C Edouard; P J Meunier
Journal: J Clin Endocrinol Metab Date: 1982-04 Impact factor: 5.958

9. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.

Authors: S Adami; N Zamberlan; M Mian; R Dorizzi; M Rossini; B Braga; D Gatti; F Bertoldo; V Locascio
Journal: Bone Miner Date: 1994-05

10. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.

Authors: Marelise E M W Eekhoff; Aeilko H Zwinderman; Dorien M A D Haverkort; Serge C L M Cremers; Neveen A T Hamdy; Socrates E Papapoulos
Journal: Bone Date: 2003-11 Impact factor: 4.398

3 in total

1. Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series.

Authors: Kousuke Iba; Junichi Takada; Takuro Wada; Toshihiko Yamashita
Journal: J Med Case Rep Date: 2010-05-31

2. Guidelines for diagnosis and management of Paget's disease of bone in Japan.

Authors: Shinjiro Takata; Jun Hashimoto; Kiyoshi Nakatsuka; Noriko Yoshimura; Kousei Yoh; Ikko Ohno; Hiroo Yabe; Satoshi Abe; Masao Fukunaga; Masaki Terada; Masaaki Zamma; Stuart H Ralston; Hirotoshi Morii; Hideki Yoshikawa
Journal: J Bone Miner Metab Date: 2006 Impact factor: 2.626

3. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors: Yair Liel; Muhammad Abu Tailakh
Journal: Endocrine Date: 2018-11-08 Impact factor: 3.633

3 in total